Abstract
Four antagonists were examined for their ability to differentiate α2A from the orthologous α2Dadrenoceptors. The antagonists were (2S,12bS) 1′, 3′-di-methylspiro(1, 3, 4, 5′, 6, 6′, 7,12b-octahydro-2H-benzo[b]furo[2,3-a]quinolizine)-2,4′-pyrimidin-2′-one (MK 912), 2-[2-(methoxy-1, 4-benzodioxanyl)imidazoline (RX 821002), efaroxan and benoxathian. The α2-autoreceptors in rabbit brain cortex were chosen as α2A- and the a2-autoreceptors in guinea-pig brain cortex as α2D-adrenoceptors. Slices of the brain cortex were preincubated with 3H-noradrenaline and then superfused and stimulated electrically by brief pulse trains (4 pulses, 100 Hz) that led to little, if any, α2-autoinhibition. 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline (UK 14,304) was used as an α2-adrenoceptor agonist.
UK 14, 304 decreased the stimulation-evoked overflow of tritium. The antagonists shifted the concentration-inhibition curve of UK 14, 304 to the right in an apparently competitive manner. Dissociation constants of the antagonists were calculated from the shifts. MK 912, RX 821002 and efaroxan had markedly higher affinity for (guinea-pig) α2D-adrenoceptors (pK d values 10.0, 9.7 and 9.1, respectively) than for (rabbit) α2A-adrenoceptors (pK d 8.9, 8.2 and 7.6, respectively). Benoxathian had higher affinity for α2A- (pK d 7.4) than for α2D-adrenoceptors (pK d 6.9). Ratios calculated from the K d values of the four compounds differentiated between α2A and α2D up to 100 fold. It is concluded that MK 912, RX 821002, efaroxan and benoxathian are antagonists with high power to differentiate α2A- from α2D-adrenoceptors.
Similar content being viewed by others
References
Arunlakshana O, Schild HO (1959) Some quantitative use of drug antagonists. Br J Pharmacol 14:48–58
Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR, Trendelenburg U (1994) International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46:121–136
Cambridge C (1981) UK-14,304, a potent and selective α2-agonist for the characterisation of α-adrenoceptor subtypes. Eur J Pharmacol 72:413–415
Chapleo CB, Myers PL, Butler RCM, Davis JA, Doxey JC, Higgins SD, Myers M, Roach AG, Smith CFC, Stillings MR, Welbourn AP (1984) α-adrenoreceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on α-adrenoreceptor activity. J Med Chem 27:570–576
Langin D, Paris H, Dauzats M, Lafontan M (1990) Discrimination between α2-adrenoceptors and [3H]idazoxan-labelled non-adrenergic sites in rabbit white fat cells. Eur J Pharmacol 188:261–272
Limberger N, Mayer A, Zier G, Valenta B, Starke K, Singer EA (1989) Estimation of pA2 values at presynaptic α2-autoreceptors in rabbit and rat brain cortex in the absence of autoinhibition. Naunyn-Schmiedeberg's Arch Pharmacol 340:639–647
Limberger N, Trendelenburg AU, Starke K (1992) Pharmacological characterization of presynaptic α2-autoreceptors in rat submaxillary gland and heart atrium. Br J Pharmacol 107:246–255
Link R, Daunt D, Barsh G, Chruscinski A, Kobilka B (1992) Cloning of two mouse genes encoding α2-adrenergic receptor subtypes and identification of a single amino acid in the mouse α2-C10 homolog responsible for an interspecies variation in antagonist binding. Mol Pharmacol 42:16–27
MacKinnon AC, Spedding M, Brown CM (1994) α2-Adrenoceptors: more subtypes but fewer functional differences. Trends Pharmacol Sci 15:119–123
Melchiorre C, Brasili L, Giardina D, Pigini M, Strappaghetti G (1984) 2-[[[2-(2, 6-dimethoxyphenoxy)ethyl]amino]-methyl]1,4-benzoxathian: a new antagonist with high potency and selectivity toward αl-adrenoceptors. J Med Chem 27:1535–1536
Michel AD, Loury DN, Whiting RL (1989) Differences between the α2-adrenoceptor in rat submaxillary gland and the α2A- and α2B-adrenoceptor subtypes. Br J Pharmacol 98:890–897
Motulsky HJ, Ransnas LA (1987) Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J 1:365–374
O'Rourke MF, Blaxall HS, Iversen LJ, Bylund DB (1994a) Characterization of [3H]RX821002 binding to alpha-2 adrenergic receptor subtypes. J Pharmacol Exp Ther 268:1362–1367
O'Rourke MF, Iversen LJ, Lomasney JW, Bylund DB (1994b) Species orthologs of the alpha-2A adrenergic receptor: the pharmacological properties of the bovine and rat receptors differ from the human and porcine receptors. J Pharmacol Exp Ther 271: 735–740
Renouard A, Widdowson PS, Millan MJ (1994) Multiple alpha 2 adrenergic receptor subtypes. I. Comparison of [3H]RX821002-labeled rat R alpha-2A adrenergic receptors in cerebral cortex to human H alpha-2A adrenergic receptors and other populations of alpha-2 adrenergic subtypes. J Pharmacol Exp Ther 270: 946–957
Pettibone DJ, Flagg SD, Totaro JA, Clineschmidt BV, Huff JR, Young SD, Chen R (1988) [3H]L-657,743 (MK-912): a new, high affinity, selective radioligand for brain α2-adrenoceptors. Life Sci 44:459–467
Ruffolo RR, Nichols AJ, Stadel JM, Hieble JP (1993) Pharmacologic and therapeutic applications of α2-adrenoceptor subtypes. Ann Rev Pharmacol Toxicol 32:243–279
Singer EA (1988) Transmitter release from brain slices elicited by single pulses: a powerful method to study presynaptic mechanisms. Trends Pharmacol Sci 9:274–276
Smith K, Gavin K, Docherty JR (1995) Investigation of the subtype of α2-adrenoceptor mediating prejunctional inhibition of cardioacceleration in the pithed rat heart. Br J Pharmacol 115:316–320
Starke K, Göthert M, Kilbinger H (1989) Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 69:864–989
Starke K, Trendelenburg AU, Limberger N (1995) Presynaptic α2-adrenoceptors: subtype determination. Pharmacol Commun 6:99–108
Stillings MR, Chapleo CB, Butler RCM, Davis JA, England CD, Myers M, Myers PL, Tweddle N, Welbourn AP, Doxey JC, Smith CFC (1985) α-adrenoreceptor reagents. 3.1.2 Synthesis of some 2-substituted 1, 4-benzodioxans as selective presynaptic α2-adrenoreceptor antagonists. J Med Chem 28:1054–1062
Trendelenburg AU, Limberger N, Starke K (1993) Presynaptic α2-autoreceptors in brain cortex: α2D in the rat and α2A in the rabbit. Naunyn-Schmiedeberg's Arch Pharmacol 348:35–45
Trendelenburg AU, Limberger N, Starke K (1995) Subclassification of presynaptic α2-adrenoceptors:α2D-autoreceptors in guinea-pig atria and brain. Naunyn-Schmiedeberg's Arch Pharmacol 352:49–57
Uhlén S, Xia Y, Chhajlani V, Felder CC, Wikberg JES (1992) [3H]-MK 912 binding delineates two α2-adrenoceptor subtypes in rat CNS one of which is identical with the cloned pA2d α2-adrenoceptor. Br J Pharmacol 106:986–995
Uhlén S, Muceniece R, Rangel N, Tiger G, Wikberg JES (1995) Comparison of the binding activities of some drugs on α2A, α2B and α2C-adrenoceptors and non-adrenergic imidazoline sites in the guinea pig. Pharmacol Toxicol 76:353–364
Waud DR (1976) Analysis of dose-response relationships. In: Narahashi T, Bianchi CP (eds) Advances in general and cellular pharmacology, vol 1, Plenum, New York, London, pp 145–178
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Trendelenburg, AU., Andreas Wahl, C. & Starke, K. Antagonists that differentiate between α2A- and α2D-adrenoceptors. Naunyn-Schmiedeberg's Arch Pharmacol 353, 245–249 (1996). https://doi.org/10.1007/BF00168625
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00168625